Here's the latest variant picture for the United Kingdom, to early February.
BA.3.2.* "Cicada" continued its sharp grew suddenly and took over dominance at 44%.
XFG.* "Stratus" continued falling to finish at 32%
#BA_3_2
Here's the latest variant picture for the United Kingdom, to late January.
XFG.* "Stratus" continued falling sharply to finish at 38%
BA.3.2.* grew suddenly and is challenging for dominance at 34%.
Here's the latest variant picture for the United Kingdom, to mid-January.
XFG.* "Stratus" remained dominant, but fell sharply to 44%
NB.1.8.1.* "Nimbus" grew steadily to 31%.
BA.3.2.* fell slightly to 20%.
This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
Here's the latest variant picture for Europe (excluding the UK), to early January.
BA.3.2.* "Cicada" showed a steady growth advantage of 7% per day (49% per week) over XFG.* "Stratus", with a crossover in late December.
Here's the latest variant picture for the United Kingdom, to early January.
BA.3.2.* soared to 70% of recent samples in Scotland.
Here's the latest variant picture for Australia, to early January.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* "Cicada", NB.1.8.1.* "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" all finished in the 22-26% range. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
Here's the latest variant picture with a global scope, to early January.
Globally from November, BA.3.2.* "Cicada" showed a growth advantage of 3.5% per day (25% per week) over XFG.* "Stratus". Recent volumes have been dominated by the US and Canada, where XFG.* is still dominant.
Here's the latest variant picture for Australia, to late December.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* finished at 27% with NB.1.8.1.* "Nimbus" just higher at 35%.
In a chaotic scene, JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" are also significant. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
Here's the latest variant picture with a global scope, to late December.
Globally BA.3.2.* "Cicada" showed a growth advantage of 5% per day (36% per week) over XFG.* "Stratus". The low sample sizes reported for late-December make this even more uncertain than usual.
Here's the latest variant picture for Europe (excluding the UK), to the end of November.
BA.3.2.* "Cicada" showed a slightly slowing growth advantage of 7% per day (49% per week) over XFG.* "Stratus", which predicts a crossover in late December.
Here's the latest variant picture for the United Kingdom, to the end of November.
For the UK, BA.3.2.* "Cicada" showed a slowing growth advantage of 3.2% per day (22% per week) over XFG.* "Stratus", which predicts a crossover in late January.
Here's the latest variant picture for South Australia, to late November.
NB.1.8.1.* "Nimbus" is dominant but generally falling, finishing at 56%. JN.1.* +DeFLuQE (led by PE.1.4) is also very significant at 37%. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
No further samples of BA.3.2.* were reported.
Here's the latest variant picture with a global scope, to late November.
Globally from October, BA.3.2.* "Cicada" showed a growth advantage of 4.7% per day (33% per week) over XFG.* "Stratus". This has been skewed downwards significantly by a massive dump from Canada, where BA.3.2.* has not been detected yet.
@carbon_compound
Das sind ja nur Namen, die irgendjemand im Internet verteilt. Aber sie sind halt eingängiger und hashtagtauglicher als zB #ba_3_2.
🤷♂️
Here's the latest variant picture for Europe (excluding the UK), to late November.
BA.3.2.* "Cicada" is showing a very strong growth advantage of 7.9% per day (55% per week) over XFG.* "Stratus", which predicts a crossover in late December.
To include the latest BA.3.2.* samples, I have rolled my reporting window forward an extra week or so. So the most recent data is even less representative than usual. The picture for those dates might change as more data is shared.
Here's the latest variant picture for the United Kingdom, to late November.
For the UK, BA.3.2.* "Cicada" is showing a strong growth advantage of 5% per day (35% per week) over XFG.* "Stratus", which predicts an imminent crossover.
To include the latest BA.3.2.* samples, I have rolled my reporting window forward an extra week. So the most recent data is even less representative than usual. The picture for those dates might change as more data is shared.
Here's the latest variant picture for Australia, to late November.
For Australia, BA.3.2.* "Cicada" is showing a steady growth advantage of 2.5% per day (18% per week) over NB.1.8.1.* "Nimbus", which predicts an imminent crossover (the data routinely lags).
Here's the latest variant picture with a global scope, to late November.
Globally from October, BA.3.2.* "Cicada" showed a strong growth advantage of 5.5% per day (39% per week) over XFG.* "Stratus". A crossover looks likely during January at that pace.
Here's the latest variant picture for Europe (excluding the UK), to mid-November.
BA.3.2.* "Cicada" is showing continued signs of growth. Recent samples have been reported from Germany and Ireland.
Here's the latest variant picture for South Australia, to late November.
NB.1.8.1.* "Nimbus" is dominant, finishing at 65%. JN.1.* +DeFLuQE (led by PE.1.4) is also significant at 26%. This scenario raises the risk of rapid reinfections, for those relying on immunity from a recent infection.
The first sample of BA.3.2.* was reported.
Client Info
Server: https://mastodon.social
Version: 2025.07
Repository: https://github.com/cyevgeniy/lmst